This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.
Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq
by Zacks Equity Research
Roche (RHHBY) voluntarily withdraws the bladder cancer indication of Tecentriq in the United States.
Momentum ETFs to Gain From the New Stimulus Optimism
by Sweta Jaiswal, FRM
Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.
Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.
Why Is Merck (MRK) Down 3.8% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $73.13, moving +1.33% from the previous trading session.
Travel ETFs Flying High on Vaccine Optimism
by Neena Mishra
Travel stocks will benefit from a return to normalcy
Stock Market News for Mar 3, 2021
by Zacks Equity Research
U.S. markets ended sharply lower on Tuesday led by selloff in tech stocks, a day after recording strong gains, as investors waited for Congress to approve another round of coronavirus relief package.
Merck (MRK) to Help J&J Make COVID-19 Vaccine to Boost Supply
by Zacks Equity Research
Merck (MRK) will use its existing facilities to manufacture and supply J&J's newly approved COVID-19 vaccine.
Wall Street Starts a Fresh Week at Record Highs
by Zacks Equity Research
Wall Street Starts a Fresh Week at Record Highs
Merck to Assist J&J Vaccine; Target Beats in Q4
by Mark Vickery
Merck will assist in the manufacture of J&J's just-released Covid-19 vaccine. Specific details are still forthcoming.
Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
Pharma Stock Roundup: SNY/GSK & PFE COVID-19 Vaccine Update, MRK's Pandion Buyout
by Kinjel Shah
Sanofi (SNY) & Glaxo (GSK) start phase II study on their COVID-19 vaccine candidate. Merck (MRK) offers to buy Pandion Therapeutics for $1.85 billion
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tempur Sealy, Beyond Meat, Moderna, AstraZeneca and Merck highlighted as Zacks Bull and Bear of the Day
Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study
by Zacks Equity Research
Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.
Is a Beat in Store for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.
Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.
Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.
AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes
by Zacks Equity Research
AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.
Top Research Reports for JPMorgan, Merck & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Merck (MRK), and NextEra (NEE).
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.